Skip to main content
SpringerLink
Log in

Ropinirole Prolonged Release

In Advanced Parkinson’s Disease

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

▴ Ropinirole prolonged release is a non-ergoline dopamine receptor agonist that is indicated for the treatment of Parkinson’s disease.

▴ Once-daily ropinirole prolonged release and threetimes-daily ropinirole immediate release have similar exposure over 24 hours. The prolonged-release formulation is associated with fewer fluctuations in plasma ropinirole concentrations.

▴ Two well designed, placebo- or active comparatorcontrolled trials examined the efficacy of ropinirole prolonged release in patients with advanced Parkinson’s disease suboptimally controlled by levodopa. In the placebo-controlled trial, 24 weeks’ therapy with ropinirole prolonged release 6–24 mg once daily reduced hours of ‘off’ time (primary endpoint) to a significantly greater extent than placebo. In the active comparator-controlled trial, significantly more ropinirole prolonged-release recipients than ropinirole immediate-release recipients maintained a ≥20% reduction from baseline in ‘off’ time at week 24 (primary endpoint).

▴ Ropinirole prolonged release 6–24 mg once daily was generally well tolerated in patients with advanced Parkinson’s disease; adverse events were generally typical of non-ergoline dopamine receptor agonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. Registered as Requip-Modutab®, ReQuip® LP, ReQuip® XL™, ReQuip® Depot and ReQuip® Prolib.

References

  1. National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/cg035niceguideline.pdf [Accessed 2007 Sep 18]

  2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001 Jun; 56(11 Suppl. 5): S1–88

    Article  CAS  Google Scholar 

  3. Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004 May 29; 363: 1783–93

    Article  CAS  Google Scholar 

  4. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66(7): 983–95

    Article  CAS  Google Scholar 

  5. National Collaborating Centre for Chronic Conditions. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006

    Google Scholar 

  6. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007 Apr 3; 68(14): 1108–15

    Article  CAS  Google Scholar 

  7. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther 2007 Dec; 29(12): 2654–66

    Article  CAS  Google Scholar 

  8. Tompson D, Oliver-Willwong, R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson’s disease. Clin Neuropharmacol. Epub 2008 Oct 23

  9. GlaxoSmithKline UK. Requip tablets: UK summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinter-Friendly.asp?documentid=2056 [Accessed 2008 Nov 17]

  10. GlaxoSmithKline. Ropinirole 2, 3, 4 and 8 mg prolongedrelease tablets: EU mutual recognition summary of product characteristics. GlaxoSmithKline, 2007 Nov 27

  11. GlaxoSmithKline. Requip® XL™ (ropinirole extended-release tablets): US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_requipxl.pdf [Accessed 2008 Nov 17]

  12. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson’s disease. Drugs 2000 Jul; 60(1): 115–37

    Article  CAS  Google Scholar 

  13. Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005; 11(3): 253–72

    Article  CAS  Google Scholar 

  14. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000 Oct; 39(4): 243–54

    Article  CAS  Google Scholar 

  15. Stocchi F, Stover NP, Giorgi L. Ropinirole 24-hour prolonged release as adjunct to L-dopa in patients with advanced Parkinson’s disease: efficacy according to baseline depression score [abstract no. 295]. Mov Disord 2007; 22Suppl. 16: S90

    Google Scholar 

  16. Hersh BP, Stover NP, Elmer LW, et al. Early efficacy of adjunctive ropinirole 24-hour in patients with advanced PD [abstract no. M-78]. Ann Neurol 2007; 62Suppl. 11: S35

    Google Scholar 

  17. Isaacson S, Pahwa R, Earl N. Ropinirole 24-hour prolongedrelease adjunctive therapy improves cardinal symptoms in patients with advanced Parkinson’s disease not optimally controlled with L-dopa [abstract no. 2.238]. Parkinsonism Relat Disord 2007; 13Suppl. 2: S108

    Google Scholar 

  18. Sethi KD, Stocchi F, Giorgi L. Ropinirole 24-hour prolonged release in advanced Parkinson’s disease: relationship between treatment response and disease severity [abstract no. 301]. Mov Disord 2007; 22Suppl. 16: S92–3

    Google Scholar 

  19. Stocchi F, Hunter B, Giorgi L, et al. An evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid

  20. Stocchi F, Hunter B, Giorgi L, et al. Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson’s disease (PD): the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid

  21. Schapira AHV, Stocchi F, Hunter B, et al. Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23–26; Madrid

  22. Watts RL, Sethi KD, Pahwa R, et al. Ropinirole 24-hour prolonged release delays the onset of dyskinesia compared with carbidopa/levodopa in patients with Parkinson’s disease treated with levodopa [abstract no. PI 138]. Eur J Neurol 2007; 14Suppl. 1: 65

    Google Scholar 

  23. Educational highlights from data presented at the XVIIth World Federation of Neurology (WFN) World Congress on Parkinson’s Disease; 2007 December 9–13; Amsterdam [online]. Available from URL: http://clienti.tio.ch/img_articoli/20080925_233206_WFNRopinirole-v2.02007.pdf [Accessed 2008 Dec 8]

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: L. Elmer, Department of Neurology, Medical College of Ohio, Toledo, Ohio, USA; K. Sethi, Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA; F. Stocchi, Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ∣ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Juliane Weber & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Juliane Weber & Gillian M. Keating

Authors
  1. Juliane Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weber, J., Keating, G.M. Ropinirole Prolonged Release. CNS Drugs 23, 81–90 (2009). https://doi.org/10.2165/0023210-200923010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0023210-200923010-00006

Keywords

Search

Navigation